Accuray Incorporated — Cyborg Score 5/10

Mixed
Medical Equipment Manufacturing - Radiation Oncology

Strategic Profile

The company's flagship CyberKnife platform is a robotic stereotactic radiosurgery system used for treating primary and metastatic tumors outside the brain. The TomoTherapy platform, including the Radixact System, enables ultra-precise treatments for approximately 50 patients per day. The company operates with a direct-to-customer sales model supplemented by distributors and group purchasing organizations internationally.

Cyborg Score Rationale

Accuray operates in a specialized medical device market with established technology and global market presence. However, recent earnings pressures, tariff impacts, and leadership transitions (new CEO appointed October 2025) create near-term uncertainty. Strong service revenue growth and debt refinancing completed provide stabilizing factors.

Top Insights

  • CyberKnife momentum remains strong with demonstrated clinical value in minimally invasive tumor treatment across multiple anatomical sites
  • Q4 FY2025 earnings missed estimates with break-even EPS; product sales impacted by tariffs and regional demand softness creating near-term headwinds
  • Leadership transition in October 2025 with new CEO appointment signals strategic reset and acceleration of transformation efforts
  • Global revenue of ~$750M (August 2025) with ~1,200 employees across 6 continents indicates established international footprint despite current challenges

Named Competitors

  • Radiation Therapy Systems — Linear accelerators and treatment planning systems
  • Radiation Therapy Systems — Precision radiation medicine and software solutions

Recent Developments

  • (October 2025) New Chief Executive Officer Steve La Neve appointed; accelerated transformation efforts announced
  • (August 2025) Q4 FY2025 results showed break-even EPS versus $0.03 consensus; strong service growth noted but product sales pressured by tariffs
  • (Q1 FY2026) Company reporting results for quarter ended September 30, 2025 in November 2025; Q2 2026 earnings call scheduled for March 3, 2026

Open the full interactive Accuray Incorporated report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →